UY34065A - Composición farmacéutica que contiene volasertib en dosificación mejorada y sus usos contra malignidades sólidas - Google Patents

Composición farmacéutica que contiene volasertib en dosificación mejorada y sus usos contra malignidades sólidas

Info

Publication number
UY34065A
UY34065A UY0001034065A UY34065A UY34065A UY 34065 A UY34065 A UY 34065A UY 0001034065 A UY0001034065 A UY 0001034065A UY 34065 A UY34065 A UY 34065A UY 34065 A UY34065 A UY 34065A
Authority
UY
Uruguay
Prior art keywords
volasertib
malignities
pharmaceutical composition
composition containing
against solid
Prior art date
Application number
UY0001034065A
Other languages
English (en)
Inventor
Taube Tillmann
Gerd Michael Munzert
Rudolph Dorothea
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46046245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34065(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY34065A publication Critical patent/UY34065A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere al uso de Volasertib o una sal o su hidrato para tratar pacientes que sufren de malignidades sólidas que incluyen malignidades sólidas avanzadas o metastásicas que comprenden una administración de alta frecuencia de Volasertib de acuerdo con un programa de dosificación específico .
UY0001034065A 2011-05-13 2012-05-11 Composición farmacéutica que contiene volasertib en dosificación mejorada y sus usos contra malignidades sólidas UY34065A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11165958 2011-05-13

Publications (1)

Publication Number Publication Date
UY34065A true UY34065A (es) 2012-11-30

Family

ID=46046245

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034065A UY34065A (es) 2011-05-13 2012-05-11 Composición farmacéutica que contiene volasertib en dosificación mejorada y sus usos contra malignidades sólidas

Country Status (15)

Country Link
US (3) US20130131069A1 (es)
EP (1) EP2707001B1 (es)
JP (1) JP2014513144A (es)
KR (1) KR20140025460A (es)
CN (1) CN103533941A (es)
AR (1) AR086390A1 (es)
AU (1) AU2012257833A1 (es)
BR (1) BR112013029182A2 (es)
CA (1) CA2835717A1 (es)
CL (1) CL2013003198A1 (es)
EA (1) EA201301265A1 (es)
IL (1) IL228882A0 (es)
MX (1) MX2013013059A (es)
UY (1) UY34065A (es)
WO (1) WO2012156283A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0797333A (ja) * 1993-08-04 1995-04-11 Takeda Chem Ind Ltd 超分子構造型集合体
CN101200457A (zh) 2003-02-26 2008-06-18 贝林格尔英格海姆法玛两合公司 二氢蝶啶酮、其制法及作为药物制剂的用途
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative

Also Published As

Publication number Publication date
US20130131069A1 (en) 2013-05-23
AU2012257833A1 (en) 2013-10-31
CN103533941A (zh) 2014-01-22
IL228882A0 (en) 2013-12-31
KR20140025460A (ko) 2014-03-04
WO2012156283A1 (en) 2012-11-22
BR112013029182A2 (pt) 2017-01-31
US20190290652A1 (en) 2019-09-26
EP2707001A1 (en) 2014-03-19
CA2835717A1 (en) 2012-11-22
MX2013013059A (es) 2014-02-20
CL2013003198A1 (es) 2014-06-20
EP2707001B1 (en) 2016-12-21
US20160303131A1 (en) 2016-10-20
AR086390A1 (es) 2013-12-11
JP2014513144A (ja) 2014-05-29
EA201301265A1 (ru) 2014-05-30

Similar Documents

Publication Publication Date Title
UY34065A (es) Composición farmacéutica que contiene volasertib en dosificación mejorada y sus usos contra malignidades sólidas
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
PH12016502132A1 (en) Aryl-or heteroaryl-substituted benzene compounds
BR112015032432A2 (pt) Conjugado de oligonucleotídeo antisense, oligômero, composição farmacêutica, uso de um oligômero ou conjugado de oligonucleotídeo antisense ou composição farmacêutica, método de tratamento da hipercolesterolemia ou de distúrbios relacionados e método in vivo ou in vitro
UY34076A (es) Composición farmacéutica que contiene volasertib en dosificación mejorada y sus usos contra tumores sólidos avanzados
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
PH12015500730A1 (en) Inhibitors of histone demethylases
BR112016020618A8 (pt) oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
IN2014MN00948A (es)
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
PH12017501688A1 (en) Intranasal benzodiazepine pharmaceutical compositions
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
MY175764A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
BR112014004577A2 (pt) inibidor pi3k para uso no tratamento de câncer ósseo ou para prevenção por metástase de células cancerosas primárias para os ossos
MY171048A (en) Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions
PE20151526A1 (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod
PH12017500923A1 (en) New dosage and use of a a2a antagonist
BR112013024196A2 (pt) complexos de gálio, composições farmacêuticas e métodos de uso
UA115307C2 (uk) Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри
CL2012002358A1 (es) Uso de una composicion farmaceutica oral que comprende: i) acido n-[8-(2-hidroxibenzoil)amino] caprilico o una sal del mismo, ii) vitamina b12 y opcionalmente iii) ácido fólico para preparar un medicamento util en el tratamiento de condicionews de deficiencia de vitamina b12.
EA201590732A1 (ru) Диспергируемая таблетка
PH12015501179A1 (en) Fixed dose pharmaceutical composition comprising mometasone and azelastine
AR089136A1 (es) Variantes de osteopontina para usar en la supresion o prevencion del crecimiento tumoral y composiciones que las contienen
AR116040A2 (es) Sal tosilato para-toluensulfonato de 4-(6-cloro-3-metil-4,10-dihidro-3h-2,3,4,9-tetraazabenzo[f]azulen-9-carbonil)-2-fluoro-bencilamida del ácido ciclopropancarboxílico